Literature DB >> 30784674

Is Sacubitril/Valsartan Antifibrotic?

Faiez Zannad1, João Pedro Ferreira2.   

Abstract

Entities:  

Keywords:  biomarkers; fibrosis; heart failure

Mesh：

Substances：

Year:  2019        PMID： 30784674     DOI： 10.1016/j.jacc.2018.11.041

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  4 in total

1.  Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction.

Authors:  Giovanni Battista Bolla; Antonella Fedele; Andrea Faggiano; Carla Sala; Gloria Santangelo; Stefano Carugo
Journal:  BMC Cardiovasc Disord       Date:  2022-05-13       Impact factor: 2.174

2.  Differential effects of low-dose sacubitril and/or valsartan on renal disease in salt-sensitive hypertension.

Authors:  Iuliia Polina; Mark Domondon; Rebecca Fox; Anastasia V Sudarikova; Miguel Troncoso; Valeriia Y Vasileva; Yuliia Kashyrina; Monika Beck Gooz; Ryan S Schibalski; Kristine Y DeLeon-Pennell; Wayne R Fitzgibbon; Daria V Ilatovskaya
Journal:  Am J Physiol Renal Physiol       Date:  2020-05-28

3.  Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-β1 Signaling in Kidney.

Authors:  Ronggui Liu; Qinqin Wang; Zhaoyan Ding; Xiaojuan Zhang; Yunping Li; Yichen Zang; Guijun Zhang
Journal:  Drug Des Devel Ther       Date:  2020-02-13       Impact factor: 4.162

4.  Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.

Authors:  Danial Sharifi Kia; Evan Benza; Timothy N Bachman; Claire Tushak; Kang Kim; Marc A Simon
Journal:  J Am Heart Assoc       Date:  2020-06-18       Impact factor: 5.501
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.